Investment
Features
FeesSafety
Academy
More
Pluang+

Compare General Motors Company (GM) vs Revvity Inc (RVTY) Price & Performance

General Motors CompanyTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

General Motors Company vs Revvity Inc — how do they compare? General Motors Company trades at $82.22 (market cap $72.17B), while Revvity Inc trades at $154.33 (market cap $16.98B). The key difference: General Motors Company is far larger — about 4.3× Revvity Inc's market cap, and General Motors Company pays the higher dividend (0.88%). Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and Revvity Inc for 12 Days on average.

GMRVTY
Market Cap
$72.17B$16.98B
Volume
4,900,3041,456,900
Sector
Consumer CyclicalHealth
52-Week High
$90.30$157.36
52-Week Low
$55.35$82.26
Typical Hold Time
83 Days12 Days
Enterprise Value
$175.15B$19.30B
Dividend Yield
0.88%0.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

General Motors Company

General Motors (GM) trades at $80.99, down 1.24% amid broader auto sector weakness. The stock shows mixed signals with bearish technical indicators but strong analyst support (66.7% buy rating) and a $102.08 consensus price target. Recent Q3 2026 sales declined 5.5% due to EV weakness and discontinued models, though the company has beaten earnings estimates for three consecutive quarters. GM benefits from regulatory savings of $20.4B through 2031 from eased fuel economy rules.

GM faces near-term headwinds from declining vehicle sales and competitive pressure from Asian automakers, but maintains solid cash flow and attractive valuation metrics (P/S 0.42). The stock offers 26% upside to analyst targets, though profitability compression and market share losses present ongoing challenges for investors.

Revvity Inc

Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.

The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GM
13% Buy87% Sell
Avg holding period · 83 Days
RVTY

No sentiment data available yet.

Top news

Latest headlines on both assets

About General Motors Company

General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.

Read more on GM →

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY →